Shults CW - Search Results

1

Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy.

Shults CW, Rockenstein E, Crews L, Adame A, Mante M, Larrea G, Hashimoto M, Song D, Iwatsubo T, Tsuboi K, Masliah E. Shults CW, et al. J Neurosci. 2005 Nov 16;25(46):10689-99. doi: 10.1523/JNEUROSCI.3527-05.2005. J Neurosci. 2005. PMID: 16291942 Free PMC article.

2

Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy.

Ubhi K, Rockenstein E, Mante M, Patrick C, Adame A, Thukral M, Shults C, Masliah E. Ubhi K, et al. Neuroreport. 2008 Aug 27;19(13):1271-6. doi: 10.1097/WNR.0b013e32830b3661. Neuroreport. 2008. PMID: 18695506 Free PMC article.

3

Alpha-synuclein overexpression in oligodendrocytic cells results in impaired adhesion to fibronectin and cell death.

Tsuboi K, Grzesiak JJ, Bouvet M, Hashimoto M, Masliah E, Shults CW. Tsuboi K, et al. Among authors: shults cw. Mol Cell Neurosci. 2005 Jun;29(2):259-68. doi: 10.1016/j.mcn.2005.03.001. Mol Cell Neurosci. 2005. PMID: 15911350

4

Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters.

Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, Masliah E. Rockenstein E, et al. Among authors: shults cw. J Neurosci Res. 2002 Jun 1;68(5):568-78. doi: 10.1002/jnr.10231. J Neurosci Res. 2002. PMID: 12111846

5

Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP.

Song DD, Shults CW, Sisk A, Rockenstein E, Masliah E. Song DD, et al. Among authors: shults cw. Exp Neurol. 2004 Apr;186(2):158-72. doi: 10.1016/S0014-4886(03)00342-X. Exp Neurol. 2004. PMID: 15026254

6

Intrastriatal injection of sonic hedgehog reduces behavioral impairment in a rat model of Parkinson's disease.

Tsuboi K, Shults CW. Tsuboi K, et al. Among authors: shults cw. Exp Neurol. 2002 Jan;173(1):95-104. doi: 10.1006/exnr.2001.7825. Exp Neurol. 2002. PMID: 11771942

7

alpha-synuclein from platelets is not phosphorylated at serine 129 in Parkinson's disease and multiple system atrophy.

Shults CW, Barrett JM, Fontaine D. Shults CW, et al. Neurosci Lett. 2006 Sep 25;405(3):223-5. doi: 10.1016/j.neulet.2006.07.006. Epub 2006 Aug 9. Neurosci Lett. 2006. PMID: 16901642

8

Calretinin-containing axons and neurons are resistant to an intrastriatal 6-hydroxydopamine lesion.

Tsuboi K, Kimber TA, Shults CW. Tsuboi K, et al. Among authors: shults cw. Brain Res. 2000 Jun 2;866(1-2):55-64. doi: 10.1016/s0006-8993(00)02219-8. Brain Res. 2000. PMID: 10825480

9

Fibroblast growth factor-2-producing fibroblasts protect the nigrostriatal dopaminergic system from 6-hydroxydopamine.

Shults CW, Ray J, Tsuboi K, Gage FH. Shults CW, et al. Brain Res. 2000 Nov 17;883(2):192-204. doi: 10.1016/s0006-8993(00)02900-0. Brain Res. 2000. PMID: 11074048

10

Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease.

Shults CW, Flint Beal M, Song D, Fontaine D. Shults CW, et al. Exp Neurol. 2004 Aug;188(2):491-4. doi: 10.1016/j.expneurol.2004.05.003. Exp Neurol. 2004. PMID: 15246848 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

101 results

Search Page

Filters